Syros Pharmaceuticals Inc

Syros Pharmaceuticals Inc(SYRS)財務資料

$0.117

-0.010 (-8.44%)收盤時

SYRS 獲利能力與利潤率

Evaluating the bottom line, Syros Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -776.96%, provide a clear picture of how effectively SYRS converts its operational activities into shareholder value.

SYRS 同業比較

In the context of the broader market, SYRS competes directly with industry leaders such as AWH and AQB. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, SYRS's gross margin of N/A stands against AWH's 63.39% and AQB's N/A. Such benchmarking helps identify whether Syros Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Financials

FY2024Q3
YoY:
-100.00%
0.00
Total Revenue
FY2024Q3
YoY:
-18.90%
-26.18M
Operating Profit
FY2024Q3
YoY:
-84.07%
-6.40M
Net Income after Tax
FY2024Q3
YoY:
-88.81%
-0.16
EPS - Diluted
FY2024Q3
YoY:
-35.06%
-20.69M
Free Cash Flow
FY2023Q4
YoY:
0.00%
100.00
Gross Profit Margin - %
FY2024Q3
YoY:
+1751.60%
-25.92K
FCF Margin - %
FY2023Q4
YoY:
+2522.11%
-16.68K
Net Margin - %

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始